您现在的位置是:主页 > 威尼斯网投app > 又一波降價藥品在路上33個品種入選第二批采購名單

又一波降價藥品在路上33個品種入選第二批采購名單
2020-01-06 23:27   来源:  www.rozanews.com   评论:0 点击:

又一波降價藥品在路上33個品種入選第二批采購名單感知中國經濟的真實溫度,見證逐夢時代的前行腳步。誰能代

感知中國經濟的真實溫度,見證逐夢時代的前行腳步。誰能代表2019年度商業最強驅動力?2020年1月9日,2019十大經濟年度人物頒獎典禮將于北京751D·PARK盛大召開,敬請期待。【】

Feel the real temperature of the Chinese economy, witness the pace of the dream-driven era. who can represent the strongest driving force for business 2019? On January 9,2020, the 2019 Big Ten Economic Person of the Year Awards ceremony will be held in Beijing 751D MARK Grand, please look forward to it. 【】

  新華社北京1月3日電(記者屈婷、張泉)國家組織藥品集中采購和使用聯合采購辦公室日前發布全國藥品集中采購文件,33個品種入選第二批國家藥品“集采”名單,涵蓋高血壓、糖尿病等重大慢性病用藥,以及抗腫瘤和罕見病用藥。

BEIJING, Jan.3(Xinhua)-- The State Organization's Office for Centralized Drug Purchase and Use of Joint Purchasing has issued a national centralized drug procurement document with 33 varieties included in the list of the second batch of national drugs, covering major chronic diseases such as hypertension and diabetes, as well as anti-tumor and rare diseases.

  按照集中采購工作安排,2020年1月17日將開標產生擬中選結果,全國各地患者將于今年4月份用上第二批集中帶量采購中選藥品。有網友評論說,又一波降價藥品已“在路上”。

According to the centralized procurement work arrangement, the bid opening will produce the result of the proposed selection on January 17,2020, and patients from all over the country will use the second batch of concentrated belt quantity to purchase the selected drugs in April this year. Some netizens commented that another wave of reduced prices had been \"on the way \".

  記者梳理發現,名單納入了阿卡波糖、格列美脲等口服降糖藥物;奧美沙坦酯、坎地沙坦酯、吲達帕胺等高血壓用藥;治療罕見病——肺動脈高壓的藥物安立生坦片,還有抗癌藥替吉奧、阿比特龍等;以及阿奇霉素、甲硝唑、克林霉素、莫西沙星、頭孢拉定等多個抗生素品種。

The reporter combed and found that the list included acarbose, glimepiride and other oral hypoglycemic drugs; omesartan ester, candesartan ester, indapamide and other hypertension medication; treatment of rare diseases-pulmonary arterial hypertension drug Anlishengtan tablets, as well as anticancer drugs tegio, abitron and so on; as well as azithromycin, metronidazole, moxifloxacin, ceflatin and other antibiotic varieties.

  值得注意的是,第二批國家藥品“集采”除了擴大品種,采購方案也更加成熟,并且在全國同步實施,顯示出藥品集中帶量采購制度已進入規范化、常態化運行。一些未納入醫保目錄的自費品種此次也加入“集采”。業內人士指出,這意味著自費藥品也將感到集中帶量采購帶來的降價“壓力”。

It is worth noting that the second batch of national drug \"collection\" in addition to expanding varieties, procurement programs are more mature, and implemented simultaneously in the country, showing that the drug centralized belt quantity procurement system has entered into a standardized, regular operation. Some of the self-funded varieties that are not included in the health care catalogue are also added to the collection this time. Industry insiders point out that this means that self-financed drugs will also feel the \"pressure\" to reduce prices brought on by concentrated purchases.

  2019年9月,第一批國家藥品“集采”擴圍到全國,與擴圍地區2018年同品種最低采購價相比,25種中選藥品平均降幅59%。

In September 2019, the first batch of national drug \"collection\" expanded to the whole country, compared with the lowest purchase price of the same varieties in the area in 2018, the average decline of 25 selected drugs was 59%.

  業內人士指出,從目前已經取得的成效看,以帶量采購的模式引導藥品降價,已成為大趨勢。這不僅包括國家“集采”名單上的藥品,也包括未納入國家“集采”的藥品。因此,2020年降價的藥品會更多,受益的患者面更廣。

Industry insiders pointed out that from the results achieved so far, with the procurement model to guide drug prices, has become a major trend. This includes not only the drugs on the national \"collection\" list, but also the drugs that are not included in the national \"collection \". As a result, there will be more drugs to reduce prices in 2020 and a wider range of patients to benefit.

  比如,近期國務院深化醫藥衛生體制改革領導小組發布的《關于進一步推廣福建省和三明市深化醫藥衛生體制改革經驗的通知》已明確,各地要積極采取單獨或跨區域聯盟等方式,按照帶量采購、招采合一、質量優先、確保用量、保證回款等要求,對未納入國家組織集中采購和使用的藥品開展帶量、帶預算采購。2020年9月底前,綜合醫改試點省份要率先進行探索,其他省份也要積極探索。

For example, the Circular on Further Promoting the Experiences of Deepening the Reform of the Medical and Health System in Fujian Province and Sanming Municipality, issued recently by the Leading Group on Deepening the Reform of the Medical and Health System of the State Council, has made it clear that all localities should actively adopt individual or cross-regional alliances to purchase drugs that are not included in the centralized procurement and use of pharmaceuticals, with a budget, in accordance with the requirements of quantity-based procurement, integration of recruitment, quality priority, ensuring the use of drugs and ensuring the return of funds. By the end of September 2020, the pilot provinces of comprehensive medical reform should take the lead in exploring, and other provinces should also actively explore.


相关热词搜索:

上一篇:FX168每周美元調查美元反彈或結束非農來襲小心意外大跌
下一篇:没有了

分享到: